Phase 3 study failed to meet one of the success criteria of the primary objective
RSV program to be discontinued
COPENHAGEN, Denmark, July 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) today announced that its Phase 3 clinical trial of MVA-BN RSV, a respiratory syncytial virus (RSV) vaccine
candidate for adults ≥60 years of age did not meet all the primary endpoints of preventing lower respiratory tract disease (LRTD) from RSV.
The final study results showed that the vaccine candidate had a 59% efficacy in preventing at least 2 pre-defined LRTD symptoms meeting one of the efficacy criteria of the study. However, when
measuring more severe LRTD based on at least 3 pre-defined symptoms, the vaccine candidate only demonstrated a 42.9% efficacy and missed the co-primary endpoint of the study.